Barclays PLC Lipocine Inc. Transaction History

Barclays PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.99 - $1.2 $23,834 - $28,890	-24,075 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$1.08 - $1.49 $18,426 - $25,422	17,062 Added 243.29%	24,075 $26,000
Q2 2021 Aug 13, 2021	SELL	$1.17 - $1.59 $17,059 - $23,183	-14,581 Reduced 67.52%	7,013 $10,000
Q1 2021 May 13, 2021	BUY	$1.38 - $2.28 $29,799 - $49,234	21,594 New	21,594 $33,000
Q3 2020 Nov 12, 2020	SELL	$1.21 - $2.23 $9,438 - $17,394	-7,800 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$0.42 - $1.26 $3,276 - $9,828	7,800 New	7,800 $10,000
Q1 2020 May 13, 2020	SELL	$0.32 - $0.77 $0 - $0	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$0.32 - $3.15 $15 - $154	-49 Reduced 98.0%	1 $0
Q3 2019 Nov 14, 2019	BUY	$1.79 - $3.33 $89 - $166	50 New	50 $0
Q1 2019 May 15, 2019	SELL	$1.46 - $2.33 $44,092 - $70,366	-30,200 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.07 - $1.63 $1,819 - $2,771	-1,700 Reduced 5.33%	30,200 $39,000
Q2 2018 Aug 14, 2018	SELL	$1.06 - $1.78 $8,587 - $14,419	-8,101 Reduced 20.25%	31,900 $41,000
Q1 2018 May 15, 2018	BUY	$1.18 - $3.46 $47,201 - $138,403	40,001 New	40,001 $61,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $394M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.